Pfizer withdraws emergency use application for COVID-19 vaccine in India

Pfizer withdraws emergency use application for COVID-19 vaccine in India

US pharmaceutical giant Pfizer has withdrawn its application for emergency use authorization of its BNT162b2 COVID-19 vaccine in India. This decision comes after a series of interactions with the Indian drug regulator, which had requested additional information regarding the vaccine. Regulatory Hurdles and Safety Concerns Initially submitted for approval in December 2020, the application faced […]

UK authorizes Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine

UK authorizes Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine

The UK has given a temporary authorization for emergency use for the BNT162b2 Covid-19 vaccine candidate developed by Pfizer and BioNTech. The emergency use authorization (EUA) from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for the mRNA vaccine candidate follows the release of positive results of a global phase 3 trial. Pfizer and […]

BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]

BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech

BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech

Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses of their jointly developed BNT162 COVID-19 vaccine candidate. Recently, the two pharma companies were granted the fast track designation from the US Food and Drug Administration (FDA) for BNT162b1 and BNT162b1 vaccines, which are two of the […]

BNT162b1 and BNT162b2 Covid-19 vaccine candidates get FDA fast track status

BNT162b1 and BNT162b2 Covid-19 vaccine candidates get FDA fast track status

Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2 virus have been given the fast track designation from the USFood and Drug Administration (FDA). The two vaccine candidates are part of the four investigational vaccine candidates that are being jointly developed by the companies under their […]